DOI:10.16636/j.cnki.jinn.2015.06.007 2 015 4 2 6 1 1 1 2 1 1. 530021 2. 530021 PubMed EMbase CBM CNKI NGC GIN TRIP CDC IDSA AAP WHO 2014 10 2 Ⅱ AGREEⅡ ICC 3 5 B AGREEⅡ6 68. 54 % Ⅱ A systematic review of evidence-based guidelines for drug therapies for viral encephalitis in children ZHANG Hong-Liang HUANG Zhen-Guang ZOU Xiao-Qin LIAO Yi-Mei LIU Tao-Tao. The Department of Pharmacy the First Affiliated Hospital of Guangxi Medical University Nanning 530021 China Corresponding author LIU Tao-Tao E-mail liutaotao66@ sohu. com Abstract Objective To systematically review the guidelines for viral encephalitis in children and to provide a reference for evidence-based medication in clinical practice. Methods The databases including PubMed EMbase CBM Wanfang Data CNKI and VIP were searched as well as the guideline databases such as NGC GIN and TRIP the websites of medical institutions including CDC IDSA AAP WHO and Chinese Health and Family Planning Committee China Guideline Clearinghouse and Clinical Practice Guideline Network. All the data were searched from the inception of the database or network to October 2014. Two investigators independently screened the literature according to inclusion and exclusion criteria and assessed the quality of guidelines with Appraisal of Guidelines for Research and Evaluation II AGREE II. The intraclass correlation coefficient was used for conformance test. Results A total of 3 guidelines from the UK US and Europe were enrolled which were released within the past 5 years. The recommendations for all three guidelines were level B. Among the 6 domains of AGREE II the domain of scope and purpose had the highest score with an average value of 68. 54% while the domains of applicability and editorial independence had lower scores. The suspected children should be given acyclovir as the empirical therapy as early as possible. Acyclovir was also recommended in patients with a confirmed diagnosis of herpes simplex virus HSV encephalitis or varicella zoster virus VZV encephalitis but the recommendation level was different. The former had a strong recommendation level while the latter had a decreased recommendation level. In addition corticosteroids were not recommended in children with HSV while it could be used as an alternative treatment of VZV e- 2015-10 - 13 2015-12 - 03 1984 - E-mail 277749097@ qq. com 1973 - E-mail liutaotao66@ sohu. com 505
Journal of International Neurology and Neurosurgery 2015 42 6 ven though the evidence was not sufficient. Ganciclovir combined with foscarnet were recommended for cytomegalovirus encephalitis while cidofovir was not recommended. Pleconaril might be a choice in patients with enterovirus encephalitis. Conclusions The drugs for the treatment of viral encephalitis recommended by these guidelines are basically consistent but the development of evidence-based guidelines should be improved in the domains of editorial independence and applicability in future. Key words child viral encephalitis Appraisal of Guidelines for Research and Evaluation II guideline systematic review virus encephalitis 2 AGREE Ⅱ 6 23 1 7 1 2 = - / Ⅱ appraisal of guidelines for research and evaluation Ⅱ AGREE Ⅱ 1 1. 1 3-5 6 1 30 % 3 2 < 60 % C 7-0 ~ 18 3 4 < 30 % 3 9 1 2 SPSS16. 0 1. 2 1 PubMed EMbase CBM CNKI 2 NGC GIN TRIP 2. 1 3 20 CDC IDSA AAP WHO 2014 10 3 3 2 viral encephalitis meningitis meningoencephalitis guideline recommendation. Pubmed 1. 3 EFNS IDSA 1 2012 IDSA 1. 4-100 % 3 A 6 60 % B 1. 5 ICC ICC 0 ~ 1 ICC < 0. 4 ICC > 0. 75 8 2 7 8 2 3 10-12 1 3 3 2008 AGREE Ⅱ 6 506
2 015 4 2 6 IDSA 2. 2. 1 EFNS 3 70 % 28 d 16 2. 2. 2 3 1 3 2 1 1 2. 2. 3 8 1 2 3 4 5 6 7 8 1 3 2 3 1 2 2. 2 3 ICC 2 2. 2. 4 ICC > 0. 75 AGREEⅡ 2 3 1 60 % 5 2 3 60 % 60 % 3 4 3 B 1 1 2012 Management of suspected viral encephalit is in children-association of British Neurologists and British Paediatric Allergy Immunology and Infection Group National Guidelines 10 11 29 211 2 2010 EFNS Viral meningoencephalitis a review of diagnostic methods and guidelines for management 12 7 14 99 3 2008 IDSA The Management of Encephalitis Clinical Practice Guidelines by the Infectious Diseases Society of America 11 10 25 126 2 AgreeⅡ 6 60% 1 70. 14% 60. 60% 73. 96% 66. 4% 61. 35% 15. 62% 5 B 2 63. 33% 34. 26% 60. 04% 63. 12% 14. 58% 12. 03% 3 B 3 72. 14% 65. 61% 61. 16% 67. 89% 16. 67% 66. 67% 4 B 2. 2. 5 4 1 4 2 1 3 507
Journal of International Neurology and Neurosurgery 2015 42 6 2. 2. 6 4 3 3 2. 3 2. 3. 1 1 3 1 6 h 3 B HHV-6 1 3 12 500 mg / m2 / 8 h 12 10 mg / kg / 8 h 3 Epstein-Barr 2. 3. 2 1 2 3 3 4 10 mg /kg 20 mg /kg /8h 14 ~ 21 d 21 d 3 ~ 12 500 mg /m 2 /8h 12 10 ~ 15 mg /kg /8h 60 ~ 80 mg /d 5 mg /kg bid 60 mg /kg /8h 5mg /kg 2 60 mg /kg / 8h 90 mg /kg 2 3 3 ~ 5 d 3 6 3 13-3 15 3 B AGREE Ⅱ6 68. 54 % 6 300 ~ 3000 2 3 3 80 % 2 508
2 015 4 2 6 5. AGREE Ⅱ 5 9 9-6 0 1. 6 AGREE Next Steps Consortium. Appraisal of guidelines for research & evaluation II EB / OL. 2 0 0 9-0 5 2015-16 0 6. http / / www. agreetrust. org. 1 7. 3. 2 0 1 3 1 3 8 9 4 7-9 5 4. 8. AGREE Ⅱ 9 17 18 D. 2 0 1 2 7 5 3 7 2-3 7 9. 9. 2011. 2013 13 6 760-763. 1 0 Kneen R Michael BD Menson E et al. Management of suspected viral encephalitis in children -Association of British Neurologists and British Paediatric Allergy Immunology and Infection Group National Guidelines. J Infect 2 0 1 2 6 4 19 5 4 4 9-4 7 7. 1 1 Tunkel AR Glaser CA Bloch KC et al. The management of encephalitis clinical practice guidelines by the infectious AIDS diseases society of America. Clin Infect Dis 2 0 0 8 4 7 3 3 0 3-3 2 7. 1 2 Steiner I Budka H Chaudhuri A et al. Viral meningoencephalitis a review of diagnostic methods and guidelines for management. Eur J Neurol 2 0 1 0 1 7 8 9 9 9-1 0 0 9. 1 3. -. 20 2 0 1 4 3 2 7 6 8 6-6 8 9. 1 4.. 2 0 1 4 3 3 8 8 5 2-8 5 8. AGREE 1 5.. 2 0 0 7 7 5 2 9 1-2 9 4. 1 6 Martinez -Torres F Menon S Pritsch M et al. Protocol for German trial of Acyclovir and Corticosteroids in Herpes -simplexvirus -encephalitis GACHE a multicenter multinational randomized double -blind placebo -controlled German Austrian and Dutch trial. BMC Neurol 2 0 0 8 8 4 0. 1 7.. 2 0 1 4 4 1 2 1 1 5-1 1 7. 1.. 7. 1 8. 2 0 0 8 4 7 6-4 7 7.. 2.. 2 0 1 4 4 1 6 4 9 7-5 0 1. 2 0 1 2 2 7 2 4 1 8 6 3-1 8 6 5. 3. AGREEⅡ. 2013 8 4 316-319.. 2 0 1 4 3 4 6 1 9.. 2005 15 8 475-476. 2 0. 4. Ⅱ. 2 0 0 7 2 3 3. 2 0 1 2 1 0 2 1 6 0-1 6 5. 3 7 5-3 7 7. 509